erbitux and Neulasta Interactions

Interactions between erbitux(cetuximab) and Neulasta (pegfilgrastim)

pegfilgrastim and cetuximab (Moderate Drug-Drug)

ADJUST DOSING INTERVAL: The safety and efficacy of granulocyte colony-stimulating factor (G-CSF) given simultaneously with cytotoxic chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because (G-CSF) stimulates myeloid cell proliferation while cytotoxic agents primarily target rapidly dividing cells.

MANAGEMENT: Because of the potential sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy, the manufacturer recommends that pegfilgrastim not be given from 14 days before until 24 hours after cytotoxic chemotherapy administration.